Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Interim Report January – March 2020

Record quarter from product segments, driven by US businesses · In local currencies, sales from product segments increased by 21 percent for the first quarter. Reported sales increased by 24 percent to 4,029 MSEK (3,258). · In local currencies, operating profit from product segments[1)] increased by 30 percent for the first quarter. Reported operating profit from product segments increased by 34 percent to 1,652 MSEK (1,233). · Operating profit amounted to 1,594 MSEK (1,190) for the first quarter. · Profit after tax amounted to 1,161 MSEK (880) for the first quarter. ·

Calliditas provides a corporate business update in the context of the Covid-19 pandemic

Calliditas Therapeutics AB (publ) (“Calliditas”) today provided an update on its business activities and financial position as well as the initiatives announced to continue to build its organization amid the evolving COVID-19 pandemic, all while promoting the continuity of the development of its late stage R&D portfolio.R&D portfolio update To date, Calliditas does not anticipate that the Covid-19 pandemic will significantly impact the ongoing clinical activities related to NefIgArd, the company’s Phase 3 pivotal trial in IgA nephropathy (IgAN). Due to the facts that the Part A of the

Herantis Pharma Oyj: Manager’s Transactions - Inveni Life Sciences Fund I Ky

Herantis Pharma PlcCompany release 27 April 2020 at 9:00 AM Eastern European Time Herantis Pharma Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Inveni Life Sciences Fund I Ky Position: Closely associated person (X) Legal person (1): Person Discharging Managerial Responsibilities In Issuer Name: Prihti, Aki Position: Member of the Board Issuer: Herantis Pharma Oyj LEI: 743700W4CQVYAT3WKK38 Notification type: INITIAL NOTIFICATION Reference number: 743700W4CQVYAT3WKK38_

Herantis Pharma Oyj: Manager’s Transactions - Inveni Capital Oy

Herantis Pharma PlcCompany release 27 April 2020 at 9:00 AM Eastern European Time Herantis Pharma Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Inveni Capital Oy Position: Closely associated person (X) Legal person (1): Person Discharging Managerial Responsibilities In Issuer Name: Prihti, Aki Position: Member of the Board Issuer: Herantis Pharma Oyj LEI: 743700W4CQVYAT3WKK38 Notification type: INITIAL NOTIFICATION Reference number: 743700W4CQVYAT3WKK38_20200423162903_6

Herantis Pharma Oyj: Manager’s Transactions - Inveni Fund I Oy

Herantis Pharma PlcCompany release 27 April 2020 at 9:00 AM Eastern European Time Herantis Pharma Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Inveni Fund I Oy Position: Closely associated person (X) Legal person (1): Person Discharging Managerial Responsibilities In Issuer Name: Prihti, Aki Position: Member of the Board Issuer: Herantis Pharma Oyj LEI: 743700W4CQVYAT3WKK38 Notification type: INITIAL NOTIFICATION Reference number: 743700W4CQVYAT3WKK38_20200423162719_6

Herantis Pharma Oyj: Manager’s Transactions - Inveni Pre-Exit Financing Vehicle Ky

Herantis Pharma PlcCompany release 27 April 2020 at 9:00 AM Eastern European Time Herantis Pharma Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Inveni Pre-Exit Financing Vehicle Ky Position: Closely associated person (X) Legal person (1): Person Discharging Managerial Responsibilities In Issuer Name: Prihti, Aki Position: Member of the Board Issuer: Herantis Pharma Oyj LEI: 743700W4CQVYAT3WKK38 Notification type: INITIAL NOTIFICATION Reference number:

Golden Heights Aktiebolag (publ) delays the publication of the Annual Report for the year ended 31[st] December 2019

Golden Heights Aktiebolag (publ) delays the publication of the Annual Report for the year ended 31[st] December 2019. New date for the publication of the Annual Report for 2019 is 21[st] May 2020. The reason for the delay of the publication is the current outbreak of the Covid-19 pandemic. For further information please visit www.iduna.se or contact Madeléne Wingård, Managing Director, madelene.wingard@iduna.se phone no. +46 340 59 54 10. Golden Heights Aktiebolag (publ) is required to publish this information in accordance with EU:s Regulation for Market Misuse and the law governing

Traumakine to be a part of WHO’s Solidarity trial

Faron Pharmaceuticals Oy("Faron" or the "Company") Traumakine to be a part of WHO's Solidarity trial investigating potential COVID-19 treatments Company announcement, 27 April 2020 at 9.00 AM (EEST)Inside information TURKU, FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces today that the Company will donate supplies of its investigational intravenous (IV) interferon (IFN) beta-1a for 2,000 patients in the World Health Organization's (WHO) Solidarity trial investigating potential COVID-19 treatments.

Detection Technology Plc business review January-March 2020

Detection Technology Plc company announcement 27 April 2020 at 09:00 (EEST) DETECTION TECHNOLOGY PLC BUSINESS REVIEW JANUARY-MARCH 2020 Demand and profitability weakened by COVID-19, healthy prospects in medical January-March 2020 highlights · Net sales decreased by -13.6% to EUR 19.9 million (23.1) · Net sales of Security and Industrial Business Unit (SBU) decreased by -20.3% to EUR 11.5 million (14.5) · Net sales of Medical Business Unit (MBU) decreased by -2.3% to EUR 8.4 million (8.6) · Operating profit (EBIT) was EUR 1.2 million (3.9) · Operating margin (EBIT-%

Nitro Games Oyj: Interim report Jan – Mar 2020

Reporting period January – March 2020 · Revenues (Jan-Mar): 461,8 KEUR (25,2 KEUR on corresponding period 2019). · EBITDA: -209,2 KEUR (-1 315,5 KEUR). · EBIT: -323,4 KEUR (-1 472,1 KEUR). · Net profit: -325,0 KEUR (-1 474,9 KEUR). · Cash and cash equivalents: 944,0 KEUR, and 460,2 KEUR of short-term receivables (31 March 2020). Significant events during January - March 2020 · Signed publishing services agreement with Expansive Worlds AB (“Avalanche Studios”). · Expanded soft launch for Heroes of Warland with biggest game expansion to date. · Updated on the

Wulff Group Plc’s Interim Report for January 1 – March 31, 2020

INTERIM REPORT  April 27, 2020 at 9.00 A.M.This is a summary of Wulff Group Plc’s Interim Report for January – March 2020. Wulff Group’s Interim Report as a whole is attached as a PDF file to this stock exchange release and it is also available on the company’s website www.wulff.fi.Netsales increased and profitability grew further 1.1.-31.3.2020 BRIEFLY · Net sales totalled EUR 14.7 million (13.8), increased by 6.4%. · EBITDA and comparable EBITDA were EUR 0.7 million (0.6). · Operating profit and comparable operating profit (EBIT) amounted to EUR 0.3 million (0.2). ·

MUNTERS TURNS 65

Virus and the climate crisis. At its 65th birthday, Munters is more relevant than ever and in a unique positioned to tackle today’s global challenges.When Carl Munters founded his company in 1955, he brought with him innovative solutions for creating the best indoor air for people and industries. Today, his air treatment solutions are more critical than ever. Energy efficient solutions One area where Munters’ products can play an important part is to reduce the world's energy consumption. “There are many industries where we see the potential to achieve a lot with our technology,”

SBB, Interim Report January – March 2020: Profit after tax per ordinary share of class A and B increased to SEK 0.94 (0.20)

SAMHÄLLSBYGGNADSBOLAGET I NORDEN AB (PUBL): Interim Report January – March 2020 in brief: • Rental income increased to SEK 1,341m (429). • The operating surplus increased to SEK 895m (240). • Cash flow from operating activities before changes in working capital was SEK 444m (97). • Profit before tax increased to SEK 1,695m (394), of which: · Profit from property management is included with SEK 319m (106). The management result includes costs for early repayment of loans and other non-recurring costs of SEK -147m (-25). · Changes in value of properties are included with

PEMA Flange Fitting station for onshore and offshore wind towers

PEMA Flange Fitting station (PEMA FF) is an ideal solution for both onshore and offshore tower production. The solution simplifies production and improves safety.   The continuously growing size of wind turbines requires larger diameters and heavier weights in flanges and tower sections, which makes the handling of these components with overhead crane more challenging and requires special skills and tools from the crane operator. With PEMA FF station, flange fitting is possible without turning the shell, and thus cranes can be released to other tasks. Also, the amount of

Hudya sells parts of customer portfolio

The Hudya AB subsidiary, Hudya Data & Tele AS, has agreed with the Norwegian telecom enabler, eRate AS, to sell parts of the Norwegian telecom customer portfolio at a price of 10.000.000,- Norwegian kroner.«This transaction is an important step in the right direction to consolidate the group and achieving a positive bottom line», states CFO of Hudya AB, Hanne Ek.“A majority of the portfolio sold consists of customers acquired through M&A. Hudya wants to focus on acquiring new customers organically, as we see a clear tendency that customers buying into the Hudya value proposition from the

Report for the first quarter 2020: Recovery, but outlook uncertain

The first quarter · Revenue was SEK 18,772 (20,017) million  · EBITDA was SEK 1,286 (2,755) million · Operating profit was SEK 343 (1,674) million · Earnings per share were SEK 0.17 (1.24)Comments by the CEO SSAB’s operating profit for the first quarter of 2020 was SEK 343 million, down SEK 1,331 million compared with the first quarter of 2019. The first quarter of last year was characterized by more favorable market conditions, especially for SSAB Americas. Compared with the fourth quarter of 2019, which was characterized by destocking, weak margins, as well as our yearly

True Corporation Thailand selects Ericsson 5G RAN

· Ericsson to enable smooth, fast and cost-effective 5G network evolution for True · Ericsson to deploy 5G RAN in three Thai regions: North; Central-West; and Upper South · Ericsson Radio System to enable 5G on 700MHz, 2.6GHz and 26GHz bandsThai communications service provider True Corporation Plc (True) has selected Ericsson (NASDAQ: ERIC) as a 5G Radio Access Network (RAN) vendor as part of its national 5G network. Products and services from Ericsson Radio System  will enable True to operate 5G on 700MHz (low-band), 2.

NCC and Taaleri to construct new apartment blocks in Espoonlahti, outside Helsinki

NCC and Taaleri Real Estate Fund are to construct three new apartment blocks in Espoonlahti, outside Helsinki, an area undergoing extensive development. In total, there will be 218 apartments of various sizes, and the order value amounts to EUR 41 M. Image: NCC Espoonlahti is an area where development is set to gather momentum, with the addition of a new metro station and the new Lippulaiva shopping center, which will open in 2023. “The seaside area of Espoonlahti is in the process of being transformed into a modern urban center, where services are close at hand for the

Read original

Arjo interim report January-March 2020

”We deliver a strong start to the year with an organic growth of 3,4%. We see clear results from our efficiency measures and our operating profit increases by over 20%, while at the same time having a solid financial position. The effects from the coronapandemic becomes clear at the end of the quarter with an increased demand for hospital beds and therapeutic mattresses, but also lower focus on products and services not directly addressing Covid-19,” says Joacim Lindoff, President & CEO. “We put an intense quarter behind us and I find it very satisfying that we can support healthcare during

First quarter results 2020: Results negatively influenced by global pandemic

27 April 2020 – Kvaerner has in the first quarter taken several precautionary steps to safeguard employees, suppliers and local societies against the risks of the corona virus development. The financial results are negatively impacted by provisions related to covid-19. For the results in 2020 as a whole, it is too early to estimate the total effects. Kvaerner has demobilised the majority of hired-in personnel working on ongoing projects, office staff is working from home offices and several virus precautions influence daily work at the yards. Still, operations are continuing, and ongoing

Sleep Cycle adds ASMR audio tracks to Sleep Aid content library

GOTHENBURG, Sweden—April 27, 2020—Sleep Cycle , the best selling alarm clock and top rated sleep tracker application, has added Autonomous Sensory Meridiam Response (ASMR) audio tracks to its Sleep Aid library, featuring a wide range collection of stories, music, ambiance and sounds.“There are millions of people around the world using ASMR as a tool to find peace and mindfulness in their days and as they fall asleep,” said Andreas Roman, Head of Content at Sleep Cycle. "Including ASMR to our Sleep Aid library is a natural next step, and one that caters to the

More than 10,000 incidents linking defence and national security to Covid-19, says Jane’s

Jane’s data highlights South American countries shifting policy direction and government instability linked to the novel coronavirus, while in Europe Spain relies on its armed forces to treat the pandemic.LONDON (27 April 2020) –– Jane’s Covid-19 Events Monitor has recorded more than 10,000 events using a combination of proprietary and open source data. The monitor – from the global agency for open source defence intelligence – looks specifically at the involvement of armed forces, government responses and the effects of the novel coronavirus outbreak on defence and national security

Alligator Bioscience presents promising interim Phase I data for its bispecific drug candidate ATOR-1015 at AACR

Lund, Sweden, April 27, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX), announces that the company today presents the status of the ongoing Phase I clinical trial with the bispecific drug candidate ATOR-1015 developed as tumor-directed therapy for metastatic cancer. The presentation will take place at the AACR (American Association for Cancer Research) Annual Meeting, which this year is being held digital for the first time. This far, doses of 400 mg (about 6 mg/kg) have been evaluated in the ongoing study and the current dosing is 600 mg (about 10 mg/kg). 18 patients with varying

The Swedish Sea Rescue Society expands its collaboration with AddSecure

The Swedish Sea Rescue Society secures its critical infrastructure with an end-to-end solution for operations and critical communications from AddSecure. The Swedish Sea Rescue Society  and AddSecure  have been collaborating for several years. AddSecure has helped the voluntary organization to build up a nationwide dispatch system, TeleCall, to quickly and efficiently call in resources that save lives along Sweden's coasts and large lakes. Now the collaboration is being expanded and the Swedish Sea Rescue

Read original
There are no items matching the current filter
There are no more items matching the current filter
Back to top